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A b s t r a c t
Introduction: Coronary artery bypass grafting (CABG) is a method of choice in treatment of diffuse coronary artery disease 
(CAD), although it has some limitations such as late saphenous vein graft (SVG) patency loss, which occurs in one fifth of all con-
duits at 5 years. Since atherosclerosis in SVG has diffuse characteristics, it appears that significantly and non-significantly stenosed 
lesions may have an equal impact on worse prognosis.
Aim: To assess non-significant lesions of SVG by the use of optical coherence tomography (OCT) and investigate the clinical and 
laboratory findings with the potential impact on plaque composition.
Material and methods: Twenty-nine patients with 43 non-significant lesions were enrolled in the study. All variables were as-
sessed using uni- and multivariable logistic regression analysis with each plaque morphology as a dependent variable. Odds ratio 
(OR) and 95% confidence interval (CI) were computed.
Results: Plaque rupture (PRT) was independently associated with age (OR = 1.49, 95% CI: 1.09–2.04, p = 0.015) and lower rates 
of high-density lipoproteins (HDL) cholesterol (OR = 0.67, 95% CI: 0.49–0.92, p = 0.016). Intimal tearing or rupture (ITR) was related 
to reduced GFR (OR = 0.52, 95% CI: 0.38–0.72, p = 0.0004). Lipid-rich plaque (LRP) was associated with raised platelet count (PLT) 
(OR = 1.51, 95% CI: 1.16–1.96, p = 0.004) and increased frequency of smoking (OR = 1.45, 95% CI: 1.12–1.89, p = 0.007).
Conclusions: Atherosclerosis of SVG is not restricted to significantly stenosed lesions. Plaque composition is independently 
associated with different types of clinical and laboratory findings, mostly recognized as risk factors of CAD.
Key words: optical coherence tomography, coronary artery disease, saphenous vein graft coronary artery bypass grafting.
S u m m a r y
The current report focuses on optical coherence tomography imaging of the saphenous vein grafts (SVG) atherosclerosis in 
non-significantly stenosed regions of the vessel wall. It demonstrates that specific clinical features and laboratory findings, as 
assessed by multivariate logistic regression analysis, have potential impact on plaque composition in these regions of the SVG.
Introduction
Coronary artery bypass grafting (CABG) is considered 
a method of choice in treatment of diffuse coronary ar-
tery disease (CAD) according to the current guidelines 
of revascularization and the reports from the SYNTAX 
trial [1–3]. The Medicare Provider and Analysis Review 
(MedPAR) database reported nearly 2.5 million CABGs 
performed between 1991 and 2005 in the United States 
(US) [4]. Despite the observed decline in the number of 
operations, the annual rate of CABGs dropped from 1742 
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in the years 2001–2002 to 1261 in the years 2005–2006, 
and the number of these procedures in the years 2007–
2008 was still 1081 per million adults in the US (average 
data from 2 years) [5]. The trend of a  reduced frequen-
cy of CABG is related to the advances in interventional 
cardiology which have been made in recent years by the 
introduction of drug-eluting stents (DES), advanced per-
cutaneous coronary intervention (PCI) techniques (rotab-
lation, bifurcation dedicated stents, mechanical circulato-
ry devices) and innovations in pharmacological treatment 
[6–8]. Nevertheless, CABG is still needed in a vast amount 
of patients not suitable for PCI. It is noteworthy that CABG 
poses many limitations, mainly related to the SVG late pa-
tency rate. Approximately 20% of saphenous vein grafts 
(SVGs) lose their patency at 5-year follow-up [9, 10], which 
is mostly caused by accelerated atherosclerosis. Risk fac-
tors of accelerated atherosclerosis are similar to those for 
native coronary atherosclerosis, but their relation to the 
SVG plaque composition was not described previously. 
Moreover, non-significant lesions are frequently associat-
ed with progression of the narrowing, which can manifest 
as acute coronary syndrome (ACS) [11, 12]. 
Aim
Therefore, the aim of the present study was to iden-
tify the variables with a  potential impact on the SVG 
plaque type as assessed by optical coherence tomogra-
phy (OCT) imaging. 
Material and methods
Study population
Twenty-nine patients hospitalized in the Upper Sile-
sia Medical Center between June 2013 and March 2016 
were enrolled in the OCTOPUS registry [13, 14]. The study 
complies with the Declaration of Helsinki and was ac-
cepted by the local ethical committee. Each patient gave 
his informed written content prior to enrollment. Inclu-
sion criteria were as follows: CABG prior to intervention 
(SVG use mandatory), acute coronary syndrome, coro-
nary artery disease with evidence of active ischemia in 
non-invasive testing. Exclusion criteria were as follows: 
lack of consent, ST-segment elevation myocardial infarc-
tion, less than 18 years of age, severe valvular insuffi-
ciency, contrast allergy, location of the lesion preventing 
safe examination. Lesions were defined as significant 
if they were involved in the initial manifestation of ACS 
assessed on the basis of clinical and non-invasive test-
ing, and/or were quantitatively (QCA) assessed as 50% 
stenosed or more. The other lesions were considered as 
non-significant and assigned for further analysis. 
OCT procedure and imaging technique
The St Jude Ilumien Optis Medical system was used 
for OCT Imaging. The OCT Dragonfly catheter was ad-
vanced through a guiding catheter over a 0.014’ guide-
wire into the SVG via a 6 Fr left radial or femoral approach. 
The OCT probe was positioned 5 mm distal to the lesion 
submitted to analysis. All OCT images were acquired us-
ing automatic pullback triggered by the hand injection 
of contrast flush. All patients were adequately heparin-
ized with the activated clotting time (ACT) > 300 s. The 
OCT image analysis was performed by an independent 
core laboratory at Krakow Cardiovascular Research In-
stitute (www.KCRI.org). In case of a conflict of opinions 
the analyzed frame was excluded from the analysis. OCT 
analysis scrutinized serial images of the vessel at every 
1 mm cross section (CS) for both significant and non-sig-
nificant de novo SVG lesions. Cross-sectional area (CSA) 
and vessel lumen diameter were measured at every 
1  mm in order to acquire the smallest values for both 
parameters, which were defined as minimal lumen di-
ameter (MLD) and minimal CSA. They were assessed for 
both types of lesions. The OCT reference lumen area and 
reference diameter were estimated at the site of the larg-
est CSA within the analyzed SVG for both de novo SVG 
lesions and non-significant lesions. Percentage lumen di-
ameter and area stenosis were defined as the relative de-
crease in luminal diameter and CSA of the target lesion 
compared to the reference lumen diameter and CSA [15].
OCT image analysis
Tissue was classified as lipid for signal-poor regions 
with diffuse borders and high signal attenuation, homo-
geneous for signal-rich regions, calcified for signal-poor 
regions with sharp edges, and heterogeneous for poor 
signal regions without signal attenuation. The length 
of an arc of lipid and calcium that occupied the ves-
sel wall circumference was measured and expressed in 
degrees [16, 17]. The thickness of the fibrous cap that 
covered the lipid core was measured in the thinnest 
part of a signal-rich zone that separated the lipid con-
tent from the vessel lumen (µm). The fibrous cap thick-
ness was a  mean value of three measurements. The 
OCT-defined thin-cap fibroatheroma (TCFA) was defined 
as a  lipid-rich plaque (LRP) with fibrous cap thickness 
< 65 µm. Also, the presence of luminal thrombus, plaque 
rupture (PRT), intimal tear or rupture (ITR), friable tissue 
(FRB), calcified plaque (CAL) and the presence of venous 
valves were noted during the OCT analysis. An intimal 
tear was defined as a micro-cavity between the SVG lu-
men and its media, an intimal rupture as a micro-cavity 
of intima connected with the SVG lumen, tissue friabil-
ity as a signal-free zone overlaid with signal-rich tissue 
inside the SVG wall [18]. Different types of SVG lesions 
are depicted in Figure 1. Offline OCT image analysis was 
performed using CAAS Intravascular 2.0 (Pie Medical 
Imaging BV). The quantitative OCT analysis was per-
formed by three observers (GK, EP and TR). If a consen-
sus could not be reached, the lesion was removed from 
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the analysis. The intraobserver variability for OCT quan-
titative measurements was presented previously [19].
Statistical analysis
Categorical variables are presented as counts and 
proportions, and the comparisons were performed using 
the χ2 test with Yates correction. The continuous vari-
ables are presented as the median and 25th to 75th per-
centile and mean ± SD. Linear variables with normal dis-
tribution were compared using Student’s t-test. Variables 
with abnormal distribution were compared using the 
Mann-Whitney U test. All variables were assessed using 
univariable logistic regression analysis with each plaque 
morphology as a dependent variable. The odds ratio (OR) 
and 95% confidence interval (CI) were computed. The 
variables fulfilling the Akaike information criterion (AIC) 
described previously [20, 21] with p < 0.1 were included 
in the primary multivariable logistic regression models of 
each plaque morphology occurrence. Additional adjust-
ments for potential confounders were performed by the 
backward stepwise method, which enabled construction 
of the final multivariable logistic regression models of 
each plaque morphology occurrence. Differences be-
tween the values were considered statistically significant 
if p < 0.05. Analyses were performed using Statistica 10 
with the medical package (StatSoft Inc.).
Results
Twenty-nine patients with 32 de novo SVG significant 
and 43 non-significant lesions were included in the study. 
The data for clinical characteristics were analyzed on 
a per patient basis and the data on plaque morphology 
were analyzed per lesion. The number of non-significant 
is greater than significant lesions because in eleven cas-
es the plaque composition was complex and presented 
more than one pathology. It necessitated the examina-
tion of an additional region of the vessel wall, which re-
sulted in an increased number of analyzed regions. Per-
cutaneous coronary intervention was performed in 22 of 
the de novo SVG lesions. For the patient characteristics 
and OCT-derived data please refer to Tables I and II re-
spectively.
All the analyzed variables were included in the uni-
variable logistic regression analysis of each plaque occur-
rence – the data are depicted in Tables III and IV. 
The variables fulfilling the AIC (marked with an as-
terisk) were included in the multivariable logistic regres-
sion models. The obtained data from the multivariable 
logistic regression analysis, after exclusion of confound-
ing factors (final models), were as follows: PRT was in-
dependently associated with age (OR = 1.49, 95% CI: 
1.09–2.04, p = 0.015) and lower serum concentration 
of high-density lipoprotein (HDL) cholesterol (OR = 0.67, 
95% CI: 0.49–0.92, p = 0.016). Intimal tear or rupture was 
related to reduced GFR (OR = 0.52, 95% CI: 0.38–0.72, 
Table I. Patients’ characteristics (n = 29)
Clinical data Results
Male, n (%) 24 (83)
Age, mean ± SD 69.07 ±7.56
Body mass index, median (IQR) [kg/m2] 28.5 (26–32)
Non-ST elevated myocardial infarction, n (%) 1 (3)
Unstable angina, n (%) 10 (35)
Stable angina, n (%) 18 (62)
Risk factors:
Hypertension, n (%) 26 (90)
Current smoking, n (%) 13 (45)
Hyperlipidemia, n (%) 25 (86)
Diabetes, n (%) 2 (7)
Time from CABG, median (IQR) [months] 143 (100–212)
Number of saphenous vein grafts, n (%):
1 4 (14)
2 18 (62)
3 7 (24)
Arterial graft (LIMA-LAD), n (%) 26 (90)
Pharmacological therapy, n (%):
β-Adrenergic antagonist 25 (86)
Calcium channel antagonist 4 (14)
Aspirin 28 (97)
Thienopyridine 2 (7)
Statin 29 (100)
ARB/ACEI 20 (69)
Other lipid-lowering therapy 6 (21)
Insulin 2 (7)
Oral antidiabetics 5 (17)
Laboratory results:
GFR, median (IQR) [ml/min/1.73 m2] 71 (53–88)
White blood cells, median (IQR) [× 103/μl] 6.32 (5.69–7.24)
Platelets, median (IQR) [× 103/μl] 184 (161–228)
Hemoglobin, median (IQR) [mg/dl] 14.08 (12.90–15.22)
Total cholesterol, mean ± SD [mg/dl] 162.29 ±58.52
LDL cholesterol, median (IQR) [mg/dl] 78 (68–98)
Triglyceride, median (IQR) [mg/dl] 132 (103–157)
HDL cholesterol, median (IQR) [mg/dl] 41 (32–48)
SD – standard deviation, IQR – interquartile range, CABG – coronary artery 
bypass grafting, LIMA-LAD – left internal mammary artery to left anterior 
descending artery, ARB – angiotensin II receptor blocker, ACEI – angiotensin-con-
verting-enzyme inhibitor, LDL – low-density lipoproteins, HDL – high-density 
lipoproteins, GFR – glomerular filtration rate.
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p = 0.0004). Lipid-rich plaque was associated with raised 
platelet count (PLT) (OR = 1.51, 95% CI: 1.16–1.96, p = 
0.004) and increased frequency of smoking (OR = 1.45, 
95% CI: 1.12–1.89, p = 0.007). The data are depicted in 
Figure 2.
On the other hand, FIB was independently associat-
ed with increased body surface area (BSA) (OR = 1.62, 
95% CI: 1.25–2.10, p = 0.001), decreased frequency of 
smoking (OR = 0.65, 95% CI: 0.50–0.84, p = 0.003) and 
hypertension (OR = 0.73, 95% CI: 0.56–0.95, p = 0.024). 
Calcified plaque was related to decreased serum con-
centration of total cholesterol (TCH) (OR = 0.73, 95% CI: 
0.54–0.99, p = 0.049) and more white blood cells (WBC) 
(OR = 1.39, 95% CI: 1.03–1.89, p = 0.036). Friable tissue 
was related to increased frequency of smoking (OR = 
1.61, 95% CI: 1.17–2.22, p = 0.006). The data are depict-
ed in Figure 3.
Discussion
According to our best knowledge, we are the first to 
address the issue of the hypothetical impact of clinical 
and laboratory findings on different plaque morphol-
ogies assessed using OCT in non-significant lesions of 
SVGs. The novelties in the study are the highly selected 
group of CABG patients with SVGs and the use of ad-
vanced statistical techniques to construct a best match-
ing prediction model of each plaque morphology. Sev-
eral imaging modalities including coronary angiography 
(CAG) and intravascular ultrasound (IVUS) have shown 
no differences in plaque composition of native vessels 
in significant vs. non-significant lesions [22, 23]. The 
PROSPECT substudy investigators found significant dif-
ferences among patients with vs. those without chron-
ic kidney disease (CKD) considering the significantly 
increased necrotic core and dense calcium [24]. These 
observations, although performed in native coronary ar-
teries, are in line with our findings that impaired renal 
function expressed as decreased GFR is independently 
associated with ITR occurrence (Figure 1). Kato et al. re-
ported that GFR (β coefficient: –6.0, p = 0.034) and diabe-
tes (β coefficient: 461.7.0, p < 0.001) were independently 
associated with lipid index in the uni- and multivariate 
linear regression models [25]. These findings are coher-
ent with our data; however, in our group only 2 patients 
had diabetes, which suggests that this aspect was sta-
tistically underpowered. Nasu et al. observed a positive 
correlation between low-density lipoprotein (LDL) choles-
terol, the percentage of necrotic core volume (r = 0.520, 
p < 0.0001) and TCFA incidence [26]. Moreover they 
found, although the difference was statistically insignif-
icant, that HDL cholesterol is decreased in patients with 
definite TCFA compared to those without (47.5 vs. 54.0, 
p = 0.39). These data are in agreement with our find-
ings that decreased HDL cholesterol is independently as-
sociated with the incidence of PRT (OR = 0.67, 95% CI: 
0.49–0.92, p = 0.016). Decreased TCH was independently 
associated with calcified plaque occurrence, which is in 
line with data from previously published large registries 
performed in patients with ACS [27, 28]. The hypercho-
lesterolemia paradox is a widely observed phenomenon 
of better outcomes in the post-ACS group of patients 
with raised TCH [29]. Statin therapy, more frequent 
medical contact prior to index disease and younger age 
are among possible triggers of this state [30]. In our 
group, all patients received statins and the correlation 
of TCH with age was statistically insignificant (r = –0.12, 
p = 0.56 – data not shown). Coolong et al. assessed the 
incidence of major adverse cardiac events (MACE) after 
stenting of SVG with embolic protection devices in differ-
ent trials published between 2002 and 2005. They found 
that smoking (OR = 1.50, 95% CI: 1.08–2.08, p = 0.01) 
and increased age per 10 years (OR = 1.21, 95% CI: 
1.07–1.37, p = 0.01) are among independent predictors of 
30-day MACE [31]. The relation between smoking and the 
Table II. Optical coherence tomography derived 
data concerning plaque characteristics
Optical coherence tomography findings Non-signifi-
cantly stenosed 
lesions (n = 43)
Region of interest, median (IQR) [mm] 11.2 (8.0–13.2)
Ref. lumen CSA, median (IQR) [mm2] 7.5 (5.6–8.7)
Ref. mean lumen diameter, median (IQR) [mm] 3.1 (2.7–3.3)
Minimal lesion lumen CSA [mm2] NA
Minimal lumen diameter, median (IQR) [mm] 2.8 (2.5–3.1)
Area stenosis, median (IQR) [%] 15.0 (13.0–17.0)
Diameter stenosis, median (IQR) [%] 0.0 (0.0–5.0) 
Maximal cap thickness, median (IQR) [μm] 140.0 (125–155)
Maximal lipid arc, median (IQR) [o] 94.0 (75–120)
Maximal calcification arc, median (IQR) [o] 107.5 (74.0–144.0)
Plaque calcification, n (%) 16 (37)
TCFA, n (%) 0 (0)
Thrombus, n (%) 0 (0)
Heterogeneous tissue, n (%) 4 (9)
Plaque rupture, n (%) 4 (9)
Lipid-rich plaque, n (%) 15 (35)
Dissection, n (%) 0 (0)
Intimal tearing, n (%) 2 (5)
Intimal rupture, n (%) 3 (7)
Tissue friability, n (%) 2 (5)
Plaque within the SVG valve, n (%) 0 (0)
CSA – cross sectional area, IQR – interquartile range, NA – not applicable, 
Ref. – reference, TCFA – thin-cap fibroatheroma, SVG – saphenous vein graft.
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progression of intermediate SVG lesions into severely ste-
nosed lesions during a median of 35 months of follow-up 
was also reported by Abdel-Karim et al. [11]. These findings 
are in line with our results which revealed that smoking 
was an independent predictor of FRB and LRP occurrence. 
Study limitations
We cannot conclude definitively whether this ad-
vanced technology could contribute to clinical practice 
in this demanding group of patients because we did not 
correlate the OCT findings with the clinical endpoints. 
Moreover, the number of study participants is relatively 
small and the investigation was performed in a  single 
center. However, the researchers did not interfere with 
the management process at any stage. It is noteworthy 
that, since OCT is an invasive procedure, there exists 
a theoretical possibility of iatrogenic damage of the ves-
sel wall, which might have influenced the results. Consid-
Table III. Univariable logistic regression analysis of multiple determinants on each plaque morphology
Parameter PRT (n = 4)
Odds ratio (95% CI), p-value
ITR (n = 5)
Odds ratio (95% CI), p-value
LRP (n = 15)
Odds ratio (95% CI), p-value
EEM vol. [mm] 0.91 (0.66–1.24), 0.531 0.92 (0.67–1.25), 0.586 1.25 (0.92–1.69), 0.153
Lumen vol. [mm] 0.94 (0.69–1.28), 0.692 0.92 (0.68–1.26), 0.617 1.23 (0.91–1.67), 0.178
Min. av. lum. diam [mm] 1.19 (0.87–1.61), 0.276 1.12 (0.82–1.53), 0.471 1.14 (0.84–1.55), 0.401
Min. lum. area [mm2] 1.18 (0.87–1.61), 0.289 1.11 (0.81–1.51), 0.519 1.13 (0.83–1.55), 0.423
Min. lum. diam. [mm] 1.13 (0.83–1.55), 0.419 1.03 (0.75–1.41), 0.857 1.22 (0.90–1.66), 0.197
Plaque vol. [mm] 0.82 (0.61–1.12), 0.209 0.91 (0.67–1.24), 0.536 1.26 (0.93–1.71), 0.130
Stenosis EEM [%] 0.93 (0.68–1.27), 0.640 0.91 (0.66–1.24), 0.530 0.99 (0.72–1.35), 0.928
Stenosis length [mm] 0.77 (0.57–1.05), 0.096* 0.85 (0.62–1.16), 0.297 1.24 (0.91–1.68), 0.170
Stenosis reference [%] 0.86 (0.63–1.17), 0.332 0.83 (0.61–1.13), 0.240 1.23 (0.90–1.67), 0.187
Surf msr. TLP [mm2] 0.85 (0.62–1.15), 0.284 0.89 (0.65–1.21), 0.450 1.27 (0.94–1.72), 0.125
Age [years] 1.31 (0.97–1.79), 0.084* 1.37 (1.01–1.85), 0.047* 1.20 (0.88–1.65), 0.250
Body surface area [m2] 0.79 (0.56–1.13), 0.196 1.35 (0.95–1.90), 0.094* 0.93 (0.65–1.33), 0.676
BMI [kg/m2] 0.80 (0.56–1.13), 0.201 0.93 (0.65–1.33), 0.690 1.00 (0.70–1.44), 0.983
LVEF [%] 0.94 (0.69–1.29), 0.714 0.58 (0.45–0.76), < 0.001* 1.12 (0.82–1.53), 0.457
Troponin [ng/l] 0.86 (0.60–1.24), 0.415 1.42 (1.01–1.99), 0.051* 1.21 (0.84–1.73), 0.298
HGB [mg/dl] 0.91 (0.66–1.25), 0.563 0.95 (0.69–1.31), 0.773 0.94 (0.68–1.29), 0.694
WBC [103/μl] 1.11 (0.81–1.53), 0.519 1.08 (0.78–1.49), 0.632 1.04 (0.76–1.43), 0.802
PLT [103/μl] 1.12 (0.82–1.54), 0.466 0.94 (0.68–1.30), 0.712 1.59 (1.20–2.11), 0.002*
TCH [mg/dl] 0.93 (0.66–1.30), 0.668 0.63 (0.47–0.85), 0.004* 1.13 (0.81–1.58), 0.473
TG [mg/dl] 1.18 (0.84–1.65), 0.337 0.74 (0.53–1.02), 0.070* 0.97 (0.69–1.37), 0.858
LDL [mg/dl] 0.92 (0.66–1.29), 0.621 0.84 (0.60–1.17), 0.308 1.08 (0.77–1.51), 0.646
HDL [mg/dl] 1.86 (1.35–2.57), 0.058* 0.96 (0.68–1.34), 0.801 0.98 (0.70–1.37), 0.897
Creatinine [mg/dl] 1.12 (0.81–1.54), 0.498 1.28 (0.93–1.75), 0.127 0.86 (0.62–1.18), 0.346
GFR [ml/min/1.73 m2] 0.94 (0.68–1.30), 0.702 0.57 (0.44–0.75), < 0.001* 1.14 (0.82–1.57), 0.428
Male 0.95 (0.69–1.30), 0.737 0.99 (0.72–1.35), 0.934 0.76 (0.56–1.02), 0.072*
Diabetes 0.85 (0.62–1.15), 0.283 1.07 (0.78–1.46), 0.683 1.03 (0.76–1.41), 0.840
Hypertension 1.14 (0.83–1.55), 0.410 1.16 (0.85–1.58), 0.350 1.34 (1.00–1.81), 0.055*
Current smoking 0.90 (0.66–1.23), 0.513 1.14 (0.84–1.56), 0.393 1.55 (1.17–2.05), 0.003*
PRT – plaque rupture, ITR – intimal tearing or rupture, LRP – lipid-rich plaque, EEM – external elastic membrane, TLP – total lumen perimeter, BMI – body mass index, 
LVEF – left ventricular ejection fraction, HGB – hemoglobin, WBC – white blood cells, PLT – platelets, TCH – total cholesterol, TG – triglycerides, LDL – low-density 
lipoproteins, HDL – high-density lipoproteins, GFR – glomerular filtration rate.
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Table IV. Univariable logistic regression analysis of multiple determinants on each plaque morphology
Paramter FIB (n = 27)
Odds ratio (95% CI), p-value
CAL (n = 16)
Odds ratio (95% CI), p-value
FRB (n = 2)
Odds ratio (95% CI), p-value
EEM vol. [mm] 1.01 (0.74–1.38), 0.960 0.93 (0.68–1.27), 0.655 0.83 (0.61–1.13), 0.225
Lumen vol. [mm] 0.98 (0.72–1.34), 0.885 0.96 (0.70–1.31), 0.800 0.84 (0.62–1.15), 0.275
Min. av. lum. diam [mm] 0.91 (0.67–1.25), 0.558 1.23 (0.91–1.67), 0.181 0.95 (0.69–1.30), 0.738
Min. lum. area [mm2] 0.94 (0.69–1.28), 0.673 1.19 (0.87–1.61), 0.274 0.95 (0.69–1.29), 0.733
Min. lum. diam. [mm] 0.89 (0.65–1.21), 0.448 1.18 (0.86–1.60), 0.299 0.94 (0.69–1.28), 0.689
Plaque vol. [mm] 1.10 (0.81–1.51), 0.529 0.86 (0.63–1.17), 0.328 0.80 (0.59–1.08), 0.150
Stenosis EEM [%] 1.19 (0.88–1.62), 0.257 0.86 (0.63–1.16), 0.316 0.87 (0.64–1.18), 0.359
Stenosis length [mm] 1.05 (0.77–1.43), 0.759 0.81 (0.60–1.10), 0.176 0.84 (0.62–1.14), 0.263
Stenosis reference [%] 0.98 (0.72–1.34), 0.898 0.79 (0.58–1.07), 0.134 0.98 (0.72–1.34), 0.883
Surf msr. TLP [mm2] 1.02 (0.75–1.39), 0.897 0.90 (0.66–1.22), 0.484 0.82 (0.61–1.12), 0.211
Age [years] 0.93 (0.68–1.28), 0.648 1.28 (0.94–1.74), 0.122 1.16 (0.85–1.59), 0.352
Body surface area [m2] 1.53 (1.11–2.12), 0.014* 0.95 (0.66–1.36), 0.764 0.81 (0.57–1.16), 0.248
BMI [kg/m2] 1.28 (0.91–1.82), 0.161 0.77 (0.54–1.08), 0.133 0.89 (0.62–1.27), 0.520
LVEF [%] 0.85 (0.62–1.16), 0.300 0.91 (0.66–1.24), 0.534 1.05 (0.77–1.43), 0.755
Troponin [ng/l] 0.80 (0.56–1.15), 0.230 1.13 (0.78–1.62), 0.512 1.36 (0.96–1.93), 0.083*
HGB [mg/dl] 1.06 (0.77–1.46), 0.708 0.81 (0.59–1.11), 0.184 0.91 (0.66–1.26), 0.575
WBC [103/μl] 0.94 (0.68–1.29), 0.697 1.35 (0.99–1.83), 0.057* 0.96 (0.70–1.32), 0.795
PLT [103/μl] 0.75 (0.55–1.02), 0.067* 0.95 (0.69–1.30), 0.739 0.94 (0.68–1.30), 0.704
TCH [mg/dl] 0.78 (0.56–1.09), 0.147 0.71 (0.52–0.98), 0.040* 1.08 (0.77–1.52), 0.634
TG [mg/dl] 0.66 (0.48–0.91), 0.013* 1.01 (0.72–1.43), 0.939 1.15 (0.82–1.61), 0.423
LDL [mg/dl] 0.80 (0.58–1.12), 0.195 0.87 (0.63–1.22), 0.428 1.04 (0.74–1.45), 0.833
HDL [mg/dl] 1.35 (0.98–1.86), 0.072* 0.68 (0.49–0.92), 0.016* 1.00 (0.71–1.40), 0.980 
Creatinine [mg/dl] 1.21 (0.88–1.67), 0.230 1.02 (0.74–1.41), 0.911 0.85 (0.62–1.17), 0.315
GFR [ml/min/1.73 m2] 0.90 (0.65–1.24), 0.510 0.83 (0.61–1.15), 0.260 1.00 (0.72–1.38), 0.996
Male 1.64 (1.25–2.16), 0.001* 1.00 (0.73–1.36), 0.985 0.63 (0.48–0.83), 0.002*
Diabetes 0.84 (0.62–1.14), 0.263 1.08 (0.79–1.48), 0.618 1.24 (0.91–1.68), 0.165
Hypertension 0.73 (0.55–0.99), 0.043* 1.36 (1.01–1.83), 0.043* 1.09 (0.80–1.49), 0.571
Current smoking 0.66 (0.50–0.88), 0.006* 0.92 (0.68–1.26), 0.606 1.36 (1.01–1.83), 0.043*
FIB – fibrotic plaque, CAL – calcified plaque, FRB – friable tissue, other abbreviations as in Table III.
ering these facts, we believe further studies are warrant-
ed in this field. 
Conclusions
Clinical and laboratory findings have an impact on 
plaque composition of non-significant lesions assessed 
with OCT. Saphenous vein graft endothelial pathology of 
non-significant lesions is associated with risk factors of 
CAD such as smoking, impaired renal function, elderly 
age, decreased HDL and raised PLT. 
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Figure 2. Logistic regression primary models of OCT-based prediction for different plaque types
HDL – high-density lipoproteins, GFR – glomerular filtration rate, LVEF – left ventricular ejection fraction.
Parameter  OR 95% CI P-value
Plaque rupture:
HDL [mg/dl] 0.70 0.51–0.95 0.028
Age [years] 1.51 1.11–2.04 0.012
Region length 0.79 0.58–1.07 0.126
Intimal tearing or rupture:
GFR [ml/min/1.73 m2] 0.61 0.39–0.95 0.037
Triglycerides [mg/dl] 0.57 0.32–1.04 0.077
Total cholesterol [mg/dl] 1.21 0.67–2.19 0.529
Troponin [ng/l] 1.54 1.00–2.38 0.060
LVEF [%] 0.92 0.64–1.33 0.669
Age [years] 1.15 0.80–1.66 0.460
Lipid rich plaque:
Platelets [× 103/μl] 1.45 1.10–1.90 0.011
Hypertension 1.18 0.89–1.55 0.247
Smoking 1.40 1.04–1.88 0.032
Male  0.95 0.70–1.28 0.730
Fibrotic tissue:
HDL [mg/dl] 1.12 0.77–1.62 0.567
Triglycerides [mg/dl] 0.97 0.67–1.42 0.891
Platelets [× 103/μl] 0.88 0.64–1.20 0.407
Hypertension 0.82 0.60–1.13 0.226
Smoking 0.75 0.52–1.10 0.150
Body surface area [m2] 1.39 0.92–2.09 0.126
Male 1.28 0.79–2.09 0.316
Calcified plaque:
HDL [mg/dl] 0.80 0.58–1.12 0.194
Total cholesterol [mg/dl] 0.79 0.58–1.08 0.150
White blood count [× 103/μl] 1.24 0.90–1.72 0.186
Hypertension 1.18 0.86–1.62 0.303
Friable tissue:
Troponin [ng/l] 1.09 0.76–1.58 0.631
Smoking  1.29 0.81–2.07 0.289
Male 0.78 0.48–1.24 0.289 
 0 1 2 3
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Figure 3. Logistic regression secondary models of OCT-based prediction for different plaque types
HDL – high-density lipoproteins, GFR – glomerular filtration rate.
Parameter  OR 95% CI P-value
Plaque rupture:
HDL [mg/dl] 0.67 0.49–0.92 0.016
Age [years] 1.49 1.09–2.04 0.015
Intimal tearing or rupture:
GFR [ml/min/1.73 m2] 0.52 0.38–0.72 < 0.001
Lipid rich plaque:
Platelets [× 103/μl] 1.51 1.16–1.96 0.004
Smoking 1.45 1.12–1.89 0.007
Fibrotic tissue:
Hypertension 0.73 0.56–0.95 0.024
Smoking 0.65 0.50–0.84 0.003
Body surface area [m2] 1.62 1.25–2.10 0.001
Calcified plaque:
Total cholesterol [mg/dl] 0.73 0.54–0.99 0.049
White blood count [× 103/μl] 1.39 1.03–1.89 0.036
Friable tissue:
Smoking 1.61 1.17–2.22 0.006 
 0 1 2 3
OR
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